Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | TFPI | P10646 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508498 | 0.95 | SIRT5 (0.45) | SIRT5SIRT2IL23RNPY1RNPY2R | |
| SCHEMBL16508502 | 0.92 | SIRT5 (0.46) | SIRT5SIRT2IL23RNPY1RNPY2R | |
| SCHEMBL16508467 | 0.90 | SIRT5 (0.44) | SIRT5SIRT2IL23RNPY1RNPY2R | |
| SCHEMBL16508436 | 0.90 | SIRT5 (0.44) | SIRT5SIRT2IL23RNPY1RNPY2R | |
| SCHEMBL16508548 | 0.90 | SIRT5 (0.44) | SIRT5SIRT2IL23RNPY1RNPY2R | |
| SCHEMBL16508552 | 0.89 | SIRT2 (0.41) | SIRT5SIRT2IL23RNPY1RNPY2R | |
| SCHEMBL30531636 | 0.88 | SIRT5 (0.51) | SIRT5SIRT2IL23RNPY1RNPY2R | |
| SCHEMBL16508439 | 0.86 | KISS1R (0.55) | NPY1RNPY2RNPY4RNPY5RKISS1R | |
| SCHEMBL16508481 | 0.85 | TLR2 (0.52) | IL23RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30974577 | 0.85 | SIRT2 (0.43) | SIRT5SIRT2IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300167-A1 | CXCR5 RECEPTOR COMPOUNDS | CXCR5, CXCR1, CCR5 | SIRT5 605/4885SIRT2 2655/4885IL23R 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.